drugset / Trial / NCT06334497
Letermovir-based Dual Therapy for Treatment of Cytomegalovirus Infections
Phase 3
Recruiting
80 enrolled
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and the tolerance of letermovir as part of dual antiviral therapy (in association with valganciclovir) in renal transplant recipients with CMV DNAemia, requiring valganciclovir treatment per investigator's judgment.
Timeline
- Start
- 2024-08-14
- Primary completion
- 2027-09
- Completion
- 2027-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Letermovir | Small molecule | 480 mg | Oral |
| Background | Valganciclovir | Small molecule | 900 mg | — |